[Metabolic syndrome and melatonin].

Area of Science:

• Biochemistry
• Endocrinology
• Metabolic Research

Background:

• Metabolic syndrome (MS) involves obesity, hypertension (AH), dyslipidemia, and insulin resistance.
• Pathophysiology includes elevated LDL, pancreatic beta-cell hyperstimulation, and altered lipid metabolism.
• Obesity leads to excess adiponectin and leptin, increasing their concentration.

Purpose of the Study:

• To investigate the role of melatonin in metabolic syndrome.
• To explore melatonin's potential therapeutic effects on MS pathophysiology.

Main Methods:

• Review of endogenous and exogenous melatonin's inhibitory mechanisms on MS pathways.
• Examination of melatonin's interaction with MT1 and MT2 receptors.
• Analysis of existing research on melatonin's therapeutic effects in MS.

Main Results:

• Melatonin inhibits MS pathophysiological mechanisms, including insulin resistance and dyslipidemia.
• It normalizes metabolism, equilibrates insulin secretion, and prevents pancreatic hyperfunction.
• Melatonin inactivates reactive oxygen and nitrogen species and phosphorylates insulin receptors.

Conclusions:

• Melatonin demonstrates a combined preventive action in MS patients due to its widespread cellular receptors.
• Emerging evidence suggests melatonin has a therapeutic effect and may be recommended for treating MS.